Navigation Links
Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Date:10/25/2011

t, Spain, Revenue ($m), 2005–2010 44

Table 16: OA Therapeutics Market, Spain, Forecast ($m), 2010–2018 46

Table 17: OA Therapeutics Market, Japan, Revenue ($m), 2005–2010 47

Table 18: OA Therapeutics Market, Japan, Forecast ($m), 2010–2018 48

Table 19: OA Therapeutics – Molecules in Pre-Registration 62

Table 20: OA Therapeutics – Phase III Pipeline 63

Table 21: OA Therapeutics – Phase II/III Pipeline 63

Table 22: OA Therapeutics – Phase II Pipeline 64

Table 23: OA Therapeutics – Phase I/II Pipeline 64

Table 24: OA Therapeutics – Phase I Pipeline 65

Table 25: OA Therapeutics – Preclinical Pipeline 66

Table 26: OA Therapeutics – Discovery Pipeline 67

Table 27: Other Mechanisms of Action from Figure 29 69

Table 28: OA Therapeutics – Promising Drugs Under Clinical Development, 2011 71

Table 29: OA Therapeutics – Clinical Trials by Country, 2011 76

Table 30: OA Therapeutics – Clinical Trials by Phase, 2011 77

Table 31: OA Therapeutics – Clinical Trials by Status, 2011 78

Table 32: OA Therapeutics, Overall Sponsors, 2011 80

Table 33: OA Therapeutics - Prominent Sponsors, 2011 82

Table 34: OA Therapeutics - Top Companies Participating in Clinical Trials, 2011 84

Table 35: BioDelivery Sciences International – Osteoarthritis Therapeutics Pipeline 89

Table 36: Cephalon, Inc. – Osteoarthritis Therapeutics Pipeline 91

Table 37: Iroko Pharmaceuticals, LLC – Osteoarthritis Therapeutics Pipeline 92

Table 38: Novartis AG – Osteoarthritis Therapeutics Pipeline 94

Table 39: SantoSolve AS – Osteoarthritis Therapeutics Pipeline 95

Table 40: Winston Pharmaceuticals, Inc. – Osteoarthritis Therapeutics Pipeline 95

Table 41: OA Therapeutics Market- Future Players 96

Table 42
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Fidia Farmaceutici S.p.A. to Distribute and Promote HYALGAN® (sodium hyaluronate) for Treatment of Osteoarthritis
2. Actress Jane Kaczmarek Teams Up With DePuy Orthopaedics to Launch Osteoarthritis Awareness and Education Program
3. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
4. Former NBA Star Allan Houston Joins "Apply Yourself!" Campaign to Raise Awareness of Osteoarthritis Hand and Knee Pain
5. The Disease Modifying Effect of Chondroitin Sulphate in Patients With Knee Osteoarthritis Has Been Confirmed by MRI
6. Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued
7. Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain
8. Logical Therapeutics Initiates Enrollment in New Gastrointestinal Safety Study in Osteoarthritis Patients
9. Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis
10. Panel of Osteoarthritis Experts Develops Optimal Profile of Exogenous Hyaluronic Acid
11. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... valves and hemodynamic monitoring, today announced that Robert A. ... "Bob is an ardent champion for innovation in ... to have him on Edwards, board as we pursue our ... chairman and CEO.  "Bob has provided a valuable perspective to ...
(Date:7/30/2015)... July 30, 2015  Tandem Diabetes Care®, Inc. ... and manufacturer of the t:slim® and t:flex™ Insulin ... non-exclusive Development Agreements with Dexcom, Inc. to allow ... with the Dexcom G5 and G6 continuous glucose ... generation pump platform with Dexcom,s future CGM systems ...
(Date:7/30/2015)... THOUSAND OAKS, Calif., July 30, 2015  Amgen ... for the second quarter of 2015. Key results ... versus the second quarter of 2014 to $5,370 ... primarily by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... ANTIPOLIS, France, May 11, 2007 /PRNewswire-FirstCall/ --,NicOx S.A. ... phase 2a,study for NCX 1000, which is covered ... A preliminary analysis of 11 patients,from this proof-of-concept ... NCX 1000 but did not demonstrate the efficacy,required ...
... 2007--Sciele Pharma, Inc.,(NASDAQ:SCRX) today announced the successful completion ... formulation. The study,results showed that the new Sular ... new Sular formulation,utilizes SkyePharma's (LSE:SKP) patented Geomatrix technology,which ... Sular for each of its,current doses. , The ...
Cached Medicine Technology:NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 2Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 4
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... The condition ... among both men and women often causing pain and discomfort. Those who spend a ... circulatory problem, and Northeast Houston Vein Center is doing what it can to create ...
(Date:8/1/2015)... ... 01, 2015 , ... On Tuesday, July 28th, Symantec released a security industry ... been behind the attack on Anthem Inc. which resulted in one of the largest ... attacks and spear phishing campaigns. , For Joe Caruso, founder and CEO/CTO ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... magazine. What are the STASH awards? The Significant Technological Achievements in Secretive ... cannabis-cultivation community as well as tried-and-true products that have stood the test of ...
(Date:7/31/2015)... IL (PRWEB) , ... July 31, 2015 , ... Ticket ... which is currently going on in Chicago at Grant Park. The festival will ... corner of North America to Chicago for the annual Lollapalooza. This unique and ...
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 , ... ... CoolSculpting , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator ... FDA in January 2014 for treating the outer thighs. The original applicator required ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... PARI,s Hydrate, a novel,medical humidifier, was awarded a ... 18, 2007. PARI Innovative Manufacturers, a leading,manufacturer of ... the way gases are heated and humidified with ... give clinicians greater control,of patient comfort. The ...
... local extinctions in a majority of species while enhancing ... the University of Illinois shows that parasites can play ... fragmented forests. This is the first study to look ... parasites on animals already stressed by disturbances to their ...
... Verathon Medical(R), the global,leader in the ... is pleased to announce that the European ... -- European Patent 1307131 B1 --,against a ... This,patent protects Verathon,s invention of its innovative, ...
... Public Schools in New York, New ... Jersey and Connecticut, ... rate monitors and fitness assessment technology, and a founding,member of the ... provide grant recipients in New York, New,Jersey and Connecticut with heart ...
... Community Urges SJHS to Agree to Fair Union Election ... and activist Ed Begley, Jr., will be among those ... St. Jude Medical,Center at a procession Saturday outside the ... workers seeking to form a union at SJHS hospitals ...
... Louis Sullivan, M.D., Former Secretary of HHS, Senator Norm ... Mark McClellan, M.D., Ph.D., and,members of the patient and ... the scientific evidence countering the United States Preventive, Services ... Screening, ARLINGTON, Va., Oct. 24 The Potomac,Institute ...
Cached Medicine News:Health News:PARI's Hydrate Wins Prestigious R&D 100 Award 2Health News:Parasites a key to the decline of red colobus monkeys in forest fragments 2Health News:Parasites a key to the decline of red colobus monkeys in forest fragments 3Health News:European Patent Office Upholds Verathon's IP Against Aircraft Medical Challenge 2Health News:Polar Joins Alliance to Combat Childhood Obesity 2Health News:Polar Joins Alliance to Combat Childhood Obesity 3Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 2Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 3Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 4Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 5
... standard in corneal diagnostics. Precise Display ... membrane, stroma, Bowman's membrane and epithelial ... Broad Applications in Surgery and Pathology. ... evaluation, endothelial cell analysis, haze detection, ...
... appearance of photo-aged skin, removes age spots ... and broken capillaries. This innovative new application ... pigmentary sun damage through a process called ... and the Nd:YAG Laser is optimized for ...
... affordable lenses available in a variety ... available in prescription powers for those ... "Plano" for those who don't. They ... technology. Incredibly comfortable, 10 fun, eye-catching ...
Each jet black lens features a mesmerizing thin white line that spirals toward the center of the pupil....
Medicine Products: